• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

Valeant fills Amgen gap as Astrazeneca hands off brodalumab; $100M up front

Sep. 2, 2015
By Marie Powers
Valeant Pharmaceuticals International Inc. picked up the brodalumab torch dropped in May by Amgen Inc., inking an exclusive license with Astrazeneca plc to develop and commercialize the interleukin (IL)-17 inhibitor in moderate to severe plaque psoriasis and psoriatic arthritis (PsA).
Read More

Thetis using 'salty' chemistry to transform diabetes care

Aug. 27, 2015
By Marie Powers
In his 35 years at Pfizer Inc., including tenure as the New York-based pharma's director of R&D operations, Frank Sciavolino was immersed in the science side of the business and didn't necessarily see himself in the role of a CEO. Despite his role as the co-founder and head of Thetis Pharmaceuticals LLC, Sciavolino opted for the title of chief scientific officer.
Read More

Beyond Lab Rats: Organ-on-a-chip efforts seek to supplant preclinical animal models

Aug. 24, 2015
By Marie Powers
Can government researchers, working in collaboration with industry and academia, build a better mousetrap for preclinical testing of therapeutic compounds that will be more predictive of their response in humans, without harming the mice? That question is at the heart of an initiative by the NIH's National Center for Advancing Translational Sciences (NCATS).
Read More

Organ-on-a-chip efforts seek to supplant preclinical animal models

Aug. 24, 2015
By Marie Powers
Can government researchers, working in collaboration with industry and academia, build a better mousetrap for preclinical testing of therapeutic compounds that will be more predictive of their response in humans, without harming the mice? That question is at the heart of an initiative by the NIH's National Center for Advancing Translational Sciences (NCATS).
Read More

Organ-on-a-chip efforts seek to supplant preclinical animal models

Aug. 21, 2015
By Marie Powers

Can government researchers, working in collaboration with industry and academia, build a better mousetrap for preclinical testing of therapeutic compounds that will be more predictive of their response in humans, without harming the mice? That question is at the heart of an initiative by the NIH's National Center for Advancing Translational Sciences (NCATS).


Read More

Celsus Therapeutics, Volution attract A-listers to tie the knot as Akari

Aug. 19, 2015
By Marie Powers
On the cusp of their nuptials, Celsus Therapeutics plc and its betrothed, Volution Immuno Pharmaceuticals SA, attracted more guests to their party.
Read More

Onconova makes good on its word with second phase III for rigosertib

Aug. 17, 2015
By Marie Powers
Onconova Therapeutics Inc. cheered investors by disclosing the submission of an investigational new drug (IND) application to the FDA to test the intravenous (I.V.) formulation of rigosertib in a pivotal phase III study in higher-risk myelodysplastic syndromes (HR-MDS) after the failure of a hypomethylating agent (HMA).
Read More

Rhythm Metabolic draws $40M series A for rare obesity disorders

Aug. 14, 2015
By Marie Powers
Propelled by a $40 million series A, Rhythm Metabolic Inc. will seek to pick up the tempo for RM-493 (setmelanotide), a peptide melanocortin-4 (MC4) agonist designed to treat obesity caused by genetic deficiencies in the MC4 pathway.
Read More

Filings up next as BCL-2 inhibitor venetoclax succeeds in CLL study

Aug. 13, 2015
By Marie Powers
Venetoclax, a small molecule designed to selectively bind and inhibit the B-cell lymphoma 2 (BCL-2) protein, was found worthy in a pivotal phase II study in previously treated patients with chronic lymphocytic leukemia (CLL) who harbor the 17p deletion, and partners Genentech Inc. and Abbvie Inc. said they'll move directly to filings with the FDA and EMA, expected by year-end.
Read More

LSK doubles down on early oncology pipeline with Huntsman deal

Aug. 12, 2015
By Marie Powers
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). The new asset doubles the cancer pipeline for the Salt Lake City-based biotech, which earlier this year completed a phase I/II trial of its lead compound, apatinib mesylate (YN968D1), in solid tumors.
Read More
Previous 1 2 … 75 76 77 78 79 80 81 82 83 … 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe